PEGASYS plus Copegus in treatment-naïve Latino patients with chronic hepatitis C-genotype 1, as compared to treatment-naïve non-Latino White patients with chronic hepatitis C-genotype 1

-
Investigator: Mandana Khalili, MD
Sponsor: Hoffman-LaRoche, Ltd.

Location(s): United States

Description

This non-randomized, open-label, two-arm study was designed to demonstrate non-inferiority of efficacy with respect to virologic response of PEGASYS plus Copegus in treatment-naive Latino patients with chronic hepatitis C, genotype 1, as compared to treatment naive non-Latino White patients with chronic hepatitis C genotype 1, both over 48 weeks of treatment, at 52 treatment centers in the US.